NEOS Investment Management LLC Makes New $226,000 Investment in Laboratory Co. of America Holdings (NYSE:LH)

NEOS Investment Management LLC acquired a new stake in shares of Laboratory Co. of America Holdings (NYSE:LHFree Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 994 shares of the medical research company’s stock, valued at approximately $226,000.

Other large investors also recently bought and sold shares of the company. Mendota Financial Group LLC bought a new stake in shares of Laboratory Co. of America in the fourth quarter worth $29,000. Provence Wealth Management Group purchased a new stake in shares of Laboratory Co. of America during the 3rd quarter valued at about $29,000. Bruce G. Allen Investments LLC purchased a new position in shares of Laboratory Co. of America in the fourth quarter worth approximately $60,000. Disciplined Equity Management Inc. bought a new stake in Laboratory Co. of America during the fourth quarter valued at approximately $68,000. Finally, Oakworth Capital Inc. raised its position in Laboratory Co. of America by 48.1% in the fourth quarter. Oakworth Capital Inc. now owns 308 shares of the medical research company’s stock worth $70,000 after acquiring an additional 100 shares during the period. 95.94% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research firms have recently commented on LH. SVB Leerink started coverage on Laboratory Co. of America in a report on Monday, February 26th. They issued an “outperform” rating and a $260.00 target price on the stock. Evercore ISI began coverage on Laboratory Co. of America in a research note on Friday, February 9th. They set an “in-line” rating and a $240.00 price objective for the company. Barclays decreased their target price on shares of Laboratory Co. of America from $234.00 to $213.00 and set an “equal weight” rating on the stock in a research note on Friday, April 26th. Argus upgraded shares of Laboratory Co. of America from a “hold” rating to a “buy” rating and set a $250.00 price target for the company in a research report on Monday, March 25th. Finally, JPMorgan Chase & Co. decreased their price objective on shares of Laboratory Co. of America from $261.00 to $243.00 and set an “overweight” rating on the stock in a research report on Thursday, May 30th. Four analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to data from MarketBeat.com, Laboratory Co. of America has an average rating of “Moderate Buy” and a consensus target price of $241.86.

Get Our Latest Research Report on LH

Laboratory Co. of America Stock Up 0.2 %

NYSE LH opened at $198.42 on Friday. The stock has a 50 day moving average price of $204.05 and a 200-day moving average price of $214.38. Laboratory Co. of America Holdings has a one year low of $180.81 and a one year high of $234.09. The company has a market capitalization of $16.73 billion, a P/E ratio of 39.92, a P/E/G ratio of 1.49 and a beta of 1.04. The company has a debt-to-equity ratio of 0.39, a quick ratio of 0.76 and a current ratio of 0.88.

Laboratory Co. of America (NYSE:LHGet Free Report) last issued its quarterly earnings data on Thursday, April 25th. The medical research company reported $3.68 EPS for the quarter, topping analysts’ consensus estimates of $3.48 by $0.20. The business had revenue of $3.18 billion during the quarter, compared to analysts’ expectations of $3.12 billion. Laboratory Co. of America had a net margin of 3.52% and a return on equity of 14.68%. The business’s revenue was up 4.6% on a year-over-year basis. During the same period last year, the company posted $3.82 EPS. As a group, equities analysts predict that Laboratory Co. of America Holdings will post 14.87 EPS for the current fiscal year.

Laboratory Co. of America Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 12th. Shareholders of record on Tuesday, May 28th will be given a dividend of $0.72 per share. The ex-dividend date of this dividend is Friday, May 24th. This represents a $2.88 dividend on an annualized basis and a yield of 1.45%. Laboratory Co. of America’s dividend payout ratio (DPR) is presently 57.95%.

Insider Activity

In related news, COO Mark S. Schroeder sold 6,477 shares of the stock in a transaction on Monday, April 1st. The stock was sold at an average price of $217.29, for a total transaction of $1,407,387.33. Following the sale, the chief operating officer now owns 5,036 shares in the company, valued at approximately $1,094,272.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other Laboratory Co. of America news, CMO Amy B. Summy sold 3,500 shares of the business’s stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $217.29, for a total transaction of $760,515.00. Following the completion of the transaction, the chief marketing officer now owns 3,975 shares in the company, valued at $863,727.75. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Mark S. Schroeder sold 6,477 shares of the company’s stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $217.29, for a total value of $1,407,387.33. Following the transaction, the chief operating officer now directly owns 5,036 shares in the company, valued at approximately $1,094,272.44. The disclosure for this sale can be found here. Insiders sold 18,469 shares of company stock valued at $3,959,058 in the last ninety days. Insiders own 0.85% of the company’s stock.

Laboratory Co. of America Profile

(Free Report)

Laboratory Corporation of America Holdings operates as a life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates in two segments, Labcorp Diagnostics (Dx) and Biopharma Laboratory Services (BLS).

See Also

Want to see what other hedge funds are holding LH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Laboratory Co. of America Holdings (NYSE:LHFree Report).

Institutional Ownership by Quarter for Laboratory Co. of America (NYSE:LH)

Receive News & Ratings for Laboratory Co. of America Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Co. of America and related companies with MarketBeat.com's FREE daily email newsletter.